The lancet Global Health : Open Access Published:July, 2021
Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood–brain barrier for late-stage infection. These procedures are inconvenient in rural health systems of disease-endemic countries. A pivotal study established fexinidazole as the first oral monotherapy to be effective against non-severe stage 2 g-HAT. We aimed to assess the safety and efficacy of fexinidazole in early g-HAT.
We thank Frederic Mistretta, Didier Not, Adrien Beauvais, and Celine Fernandez (Randomised Controlled Trials, also known as RCTs) for data management and statistical analysis;